Welcome!

News Feed Item

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

NEW YORK, Nov. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

http://www.reportlinker.com/p0332347/Partnerships-Licensing-Investments-...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

Summary

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena. - Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.- Analysis of partnership and licensing deals based on clinical stage of development of products.-

Summary

of the pharmaceutical deals globally in the last five quarters.- Information on the top deals happened in the pharmaceutical industry.- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.- Find out the major deal performing segments for investments in your industry.- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.- Identify companies that are aggressively looking to raise capital in the market- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.- Identify growth segments and opportunities in each region within the industry.- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 62 Industry Insights 83 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2012 93.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2012 93.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2012 113.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2012 123.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2012 133.4.1 Aetna to Acquire Coventry Health Care, Provider of Healthcare Services, for up to $7.3 Billion 133.4.2 WellPoint Extends Antitrust Clearance Approval to Acquire Amerigroup for $4.9 Billion 143.4.3 Linde Completes Acquisition of Lincare, Provider of Respiratory Therapy Services, for $4.6 Billion 143.4.4 Valeant Pharma to Acquire Medicis Pharma, Developer of Treatment for Dermatology and Aesthetics Conditions, for up To $2.6 Billion 143.4.5 Health Care REIT to Acquire Sunrise Senior Living for $1.9 Billion 154 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 164.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2012 164.1.1 Top M&A Deals in Q3 2012 174.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2011 - Q3 2012 184.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2012 194.2.1 Top Initial Public Offerings in Q3 2012 204.2.2 Top Secondary Offerings in Q3 2012 204.2.3 Top PIPE Deals in Q3 2012 204.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2011–Q3 2012 214.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2011 – Q3 2012 224.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2012 234.3.1 Top Venture Financing Deals in Q3 2012 244.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2012 244.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2012 254.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2011 - Q3 2012 264.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 274.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 284.3.7 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2012 294.3.8 Top Private Equity Deals in Q3 2012 304.3.9 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2011 - Q3 2012 315 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2012 325.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2012 325.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2011 - Q3 2012 345.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 355.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2012 365.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2012 365.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2012 375.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 385.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2011 - Q3 2012 395.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2011 - Q3 2012 405.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 416 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2012 426.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2012 426.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 436.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2012 446.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2012 446.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2012 456.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2011 - Q3 2012 466.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2011 - Q3 2012 476.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2011 - Q3 2012 486.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2011 - Q3 2012 496.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2011 - Q3 2012 507 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 517.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2011 - Q3 2012 517.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2011 - Q3 2012 527.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012 537.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2011 - Q3 2012 547.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2011 - Q3 2012 557.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2011 - Q3 2012 567.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012 578 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 588.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2012 588.1.1 Oncology – Deals of the Quarter 598.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2012 618.2.1 Central Nervous System – Deals of the Quarter 628.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2012 638.3.1 Infectious Disease – Deals of the Quarter 648.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2012 658.4.1 Immunology – Deals of the Quarter 668.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2012 688.5.1 Metabolic Disorders – Deals of the Quarter 698.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2012 708.6.1 Cardiovascular – Deals of the Quarter 718.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2012 728.7.1 Gastrointestinal – Deals of the Quarter 738.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q3 2012 748.8.1 Hematological Disorders – Deals of the Quarter 758.9 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2012 778.9.1 Dermatology – Deals of the Quarter 788.10 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2012 798.10.1 Respiratory – Deals of the Quarter 809 Deal Summary by Geography 819.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2012 819.1.1 North America – Deals of the Quarter 829.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2012 839.2.1 Europe – Deals of the Quarter 849.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2012 859.3.1 Asia-Pacific – Deals of the Quarter 869.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2012 889.4.1 Rest of the World – Deals of the Quarter 8910 Pharmaceuticals & Healthcare, Global, Top Advisors 9010.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 9010.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 9111 Appendix 9212 Further Information 9612.1 Methodology 9612.2 About GlobalData 9612.3 Contact Us 9712.4 Disclosure information 9712.5 Disclaimer 97

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 10Table 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (%), Q3 2012 12Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2012 13Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 – Q3 2012 17Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2012 17Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2011 - Q3 2012 18Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 19Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2012 20Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2012 20Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2012 20Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2011–Q3 2012 21Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 22Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 23Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2012 24Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2012 25Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 26Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2011 – Q3 2012 27Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2011 – Q3 2012 28Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 – Q3 2012 29Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2012 30Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 31Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 33Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 34Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 35Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 36Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2012 36Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2012 37Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 38Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 40Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 41Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 42Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 43Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2012 44Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2012 44Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2012 45Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 46Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2011 - Q3 2012 47Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 49Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 50Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2011 - Q3 2012 51Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2011 - Q3 2012 52Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012 53Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2011 - Q3 2012 54Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q3 2012 55Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2011 - Q3 2012 56Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012 57Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 59Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 62Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 64Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 66Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 69Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 70Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 73Table 54: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 75Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 78Table 56: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 80Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 82Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 84Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 86Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 89Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 90Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 91Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q3 2011-Q3 2012 92

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 9Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), Q3 2012 11Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2012 12Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 16Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2011 – Q3 2012 18Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 19Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2011 – Q3 2012 22Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 23Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2012 24Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2012 25Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2011 - Q3 2012 26Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2011 – Q3 2012 27Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2011 – Q3 2012 29Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2011 - Q3 2012 31Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 32Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 34Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 35Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 38Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 39Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 40Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 41Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 42Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 43Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 46Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 47Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2011 - Q3 2012 48Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2011 - Q3 2012 49Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 50Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2011 - Q3 2012 51Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2011 - Q3 2012 52Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012 53Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2011 – Q3 2012 54Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2011 - Q3 2012 55Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2011 - Q3 2012 56Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012 57Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 58Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 61Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 63Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 65Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 68Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 70Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 72Figure 43: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 74Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 77Figure 45: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 79Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 81Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 83Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 85Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 88Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 90Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 91

Companies Mentioned

To order this report:Investment_Banking Industry: Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

Contact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone in...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...